Blaming placebo response for 'uninterpretable' PhIII results, ContraFect calls for new antibiotic study
Having spent the past few months combing through the data from a Phase III trial that it stopped for futility, ContraFect concluded that it still hasn’t gotten to the bottom of whether its antibiotic works in a type of staph infection.
In fact, given the response rates and safety profile it’s seen so far, the biotech says another trial should be conducted on the drug, exebacase, in the same patient population — either by ContraFect itself or by a partner.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.